## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `tesamorelin-ibd`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/tesamorelin-ibd/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tesamorelin-ibd/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tesamorelin-ibd/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/tesamorelin-ibd/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tesamorelin-ibd/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/tesamorelin-ibd/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `tesamorelin-ibd` v2 · content_hash `134ca73b86073531…` · thread_head genesis · 23 DIVs
- **thesis (c1):** Tesamorelin reduces visceral adipose tissue in HIV patients per multiple RCTs.
  - c2 [human/active] No human trials have tested Tesamorelin in IBD patients.
  - c3 [human/active] Recombinant GH improved CDAI scores in a small double-blind Crohn's trial.
  - c4 [preclinical/active] GH overexpression improved mucosal repair in DSS colitis mouse models.
  - c5 [anecdotal/active] Reddit mentions of Tesamorelin in IBD contexts are limited to speculative stacks.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/tesamorelin-ibd/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/tesamorelin-ibd/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `tesamorelin-ibd`
- **title:** Tesamorelin for IBD: Growth Hormone Axis Evidence in Crohn's and Colitis
- **url:** https://miscsubjects.com/a/tesamorelin-ibd
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:23.490Z
- **tags:** peptide, matrix

## Body

## What's breaking down if you have IBD (Crohn's / colitis)

IBD involves ongoing damage to the intestinal lining where inflammation outpaces repair. Layers include barrier breakdown that lets contents leak, chronic cytokine-driven inflammation, impaired mucosal healing, and possible systemic effects like altered metabolism. GH and IGF-1 pathways support epithelial and mesenchymal cell growth plus immune cell balance in gut tissue. When these signals weaken or inflammation blocks them, repair lags and symptoms persist. Tesamorelin enters the discussion here because it raises endogenous GH via GHRH stimulation, which preclinical work links to trophic effects on gut cells.

## Why Tesamorelin might help you

1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.
2. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.

If your IBD includes metabolic or visceral fat contributions that add systemic load, the GH axis route may intersect with tissue repair signals studied in growth factor research. Tesamorelin raises GH and IGF-1 levels in human trials focused on fat reduction. Those same signals show trophic effects on intestinal cells in separate GH studies. The logic chain stays at the repair layer: elevated GH could support epithelial survival and mucosal recovery if that pathway is relevant to your breakdown profile.

## How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- **Tesamorelin** → GH axis / visceral fat

This keeps the discussion on one degeneration layer per compound without overlap.

## What the evidence actually shows

Human data on Tesamorelin itself comes from HIV lipodystrophy trials (preclinical|mechanistic|speculative tiers do not apply here). Multiple randomized placebo-controlled trials showed visceral adipose tissue reduction and lipid improvements after 26 weeks of daily 2 mg subcutaneous tesamorelin. One trial also measured modest liver fat reduction. No human trial has tested Tesamorelin in IBD patients (human tier: none).

Separate human evidence exists for recombinant GH in Crohn's disease. One double-blind placebo-controlled study in 37 patients with moderate-to-severe active Crohn's gave GH for 4 months and reported greater CDAI reduction versus placebo (human tier). Preclinical work in DSS colitis mouse models showed GH overexpression improved inflammation resolution and mucosal repair (preclinical tier).

Tesamorelin's effect on GH/IGF-1 is documented in HIV cohorts but never linked directly to IBD outcomes in controlled human studies (human tier: absent for this condition).

## What scientists say

Growth factor reviews note GH and IGF-1 relevance to IBD via effects on epithelial cells, mesenchymal cells, and immune balance. IL-6 may blunt IGF-1 response in Crohn's. Scientists emphasize these are mechanistic observations, not treatment recommendations. No publications position Tesamorelin as an IBD agent.

## What people say on Reddit

Reddit threads mention Tesamorelin in speculative IBD stacks alongside other peptides for metabolic or reparative support. One post describes a hypothetical mouse study combining multiple compounds including Tesamorelin for DSS colitis reversal (anecdotal tier). User reports of personal Tesamorelin use in Crohn's remain absent or limited to general fat-loss comments unrelated to gut symptoms (anecdotal tier: sparse, indirect).

## What people say on X

Posts referencing Tesamorelin and IBD or gut conditions are essentially nonexistent. One unrelated post lists Tesamorelin among peptides in a gut-health context without outcome details (anecdotal tier: negligible).

## What we do not know

No human trials exist for Tesamorelin in IBD. Effects on intestinal barrier, cytokine profiles, or remission rates remain untested. Duration, dosing relevance, and long-term gut-specific outcomes are unknown. Translation from HIV visceral-fat data or GH Crohn's data to this setting stays speculative.

## Safety and limits

Tesamorelin carries documented side effects from HIV trials including injection-site reactions, joint pain, and possible glucose changes. Any use outside approved indications lacks safety data in IBD populations. Evidence grading here separates clearly: strong human data for visceral fat reduction, zero human data for IBD, mechanistic overlap via GH axis only.

## Claims (5)

- **c1** [human w=0.8] Tesamorelin reduces visceral adipose tissue in HIV patients per multiple RCTs.
  - who_claims: grok/grok-4.3
  - sources: s1, s2
- **c2** [human w=0.8] No human trials have tested Tesamorelin in IBD patients.
  - who_claims: grok/grok-4.3
- **c3** [human w=0.8] Recombinant GH improved CDAI scores in a small double-blind Crohn's trial.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c4** [preclinical w=0.5] GH overexpression improved mucosal repair in DSS colitis mouse models.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c5** [anecdotal w=0.3] Reddit mentions of Tesamorelin in IBD contexts are limited to speculative stacks.
  - who_claims: grok/grok-4.3
  - sources: s4

## Voxel graph (5 atoms · 10 edges)
- full graph: https://miscsubjects.com/api/articles/tesamorelin-ibd/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (4)
- chain valid: yes · head: `1da3e168618bd1b1`

### s1 · pubmed · ok
- title: Effects of tesamorelin in HIV patients with excess abdominal fat
- url: https://pubmed.ncbi.nlm.nih.gov/20554713/
- summary: Pooled phase 3 analysis showing visceral fat reduction.
- quote: Treatment with tesamorelin reduces VAT and maintains the reduction for up to 52 wk
- claim_ids: c1
- hash: `aac2ffeddacfc751`

### s2 · pubmed · ok
- title: Efficacy and safety of tesamorelin in people with HIV
- url: https://pubmed.ncbi.nlm.nih.gov/38905488/
- summary: Confirms approved human use for visceral fat.
- quote: Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV
- claim_ids: c1
- hash: `a3635a61191a8c2a`

### s3 · pubmed · ok
- title: Growth Factors as Treatment for Inflammatory Bowel Disease
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC2841424/
- summary: Reviews GH/IGF-1 in IBD plus the human Crohn's GH trial and mouse data.
- quote: A double-blind and placebo-controlled study in 37 patients with moderate-to-severe active Crohn's disease showed that therapy with recombinant GH may be a beneficial treatment.
- claim_ids: c3, c4
- hash: `e504511778e61ddf`

### s4 · reddit · ok
- title: Peptide Research for Crohn's Disease
- url: https://www.reddit.com/r/PeptidePathways/comments/1sb0nxo/peptide_research_for_crohns_disease/
- summary: Speculative stack mention in hypothetical IBD context.
- quote: Tesamorelin elevates GH/IGF-1 for metabolic and reparative support.
- claim_ids: c5
- hash: `1da3e168618bd1b1`

## Provenance (2 model passes)
- chain valid: yes · head: `5ef59e84c673591e`

- write · grok/grok-4.3 · 2026-06-29T23:20 · hash `a997429b28f9`
- voxel_divide · owner · 2026-07-17T02:42 · hash `5ef59e84c673`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/tesamorelin-ibd/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/tesamorelin-ibd/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"tesamorelin-ibd","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest tesamorelin-ibd|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim tesamorelin-ibd|tier|assertion`
- **iMessage ask:** `tesamorelin-ibd|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `tesamorelin-ibd`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tesamorelin-ibd/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tesamorelin-ibd/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*